Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, accounting for approximately 25–30% of all newly diagnosed lymphoma cases, according to the American Cancer Society. It is an aggressive cancer of the lymphatic system that requires prompt diagnosis and treatment, yet many patients can achieve long-term remission with modern therapies.
Key Takeaways
- DLBCL is the most common aggressive non-Hodgkin lymphoma, originating from B lymphocytes.
- Risk factors include age, immune deficiency, certain infections, and family history.
- Diagnosis relies on tissue biopsy, imaging, and the Ann Arbor staging system.
- Standard first-line treatment is R-CHOP chemotherapy, with emerging targeted and cellular therapies available.
- Approximately 60–70% of patients achieve complete remission with first-line treatment; prognosis depends on stage and molecular subtype.
What Is DLBCL (Diffuse Large B Cell Lymphoma)?
Diffuse large B cell lymphoma is a fast-growing cancer that arises from B lymphocytes, a type of white blood cell that normally helps the immune system fight infection. In DLBCL, these cells transform into malignant large B cells that proliferate rapidly and spread diffusely throughout lymph node tissue, hence the name. The disease can originate in lymph nodes or in extranodal sites such as the stomach, brain, bone, or skin, making its clinical presentation highly variable.
DLBCL is classified under aggressive non-Hodgkin lymphomas by the World Health Organization (WHO) and represents a biologically diverse group of tumors. The WHO classification recognizes several molecular subtypes, including germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes, which differ in their genetic profiles and responses to therapy. Understanding these distinctions has become essential for tailoring treatment strategies.
Unlike indolent lymphomas that grow slowly over years, DLBCL progresses rapidly over weeks to months. While this aggressiveness demands urgent attention, it also means the disease is often more sensitive to intensive chemotherapy regimens. Early recognition of symptoms and immediate referral to a hematologist-oncologist are critical steps in achieving the best possible outcome.
DLBCL Causes, Risk Factors, and Symptoms
The precise cause of DLBCL in most patients remains unknown. However, the disease arises from genetic mutations and chromosomal rearrangements within B lymphocytes that disrupt normal cell growth and death pathways. Translocations involving the BCL2, BCL6, and MYC genes are among the most clinically significant, and cases with concurrent rearrangements in MYC plus BCL2 or BCL6 are classified as “double-hit” or “triple-hit” lymphomas, which carry a particularly aggressive clinical course.
Several established risk factors increase an individual’s likelihood of developing DLBCL. Advanced age is the strongest demographic risk factor, with the median age at diagnosis around 64 years. Other recognized risk factors include:
- Immunosuppression, whether from HIV/AIDS, organ transplantation, or long-term immunosuppressive medications
- Prior infection with Epstein-Barr virus (EBV) or Helicobacter pylori
- Autoimmune conditions such as Sjögren’s syndrome and rheumatoid arthritis
- Prior treatment with radiation or certain chemotherapy agents
- Family history of lymphoma or other blood cancers
The symptoms of DLBCL can vary depending on where the lymphoma originates and how extensively it has spread. The most common presenting sign is a rapidly enlarging, painless lymph node, typically in the neck, armpit, or groin. Systemic “B symptoms” — which include unexplained fever above 38°C, drenching night sweats, and unintentional weight loss exceeding 10% of body weight over six months — are present in roughly one-third of patients and are associated with more advanced disease. Additional symptoms may include fatigue, shortness of breath, abdominal swelling, or neurological changes if the central nervous system is involved.
Diagnosing and Staging Diffuse Large B Cell Lymphoma
A definitive diagnosis of DLBCL requires a tissue biopsy, typically an excisional lymph node biopsy that provides sufficient material for histological, immunohistochemical, and molecular analysis. A fine-needle aspiration alone is generally insufficient because the overall architecture of the lymph node must be assessed. Pathologists look for the hallmark large, atypical B cells that stain positive for CD20, CD19, and other B cell markers on immunohistochemistry.
Once the diagnosis is confirmed, a comprehensive staging workup is performed to determine the extent of disease. This workup typically includes positron emission tomography-computed tomography (PET-CT) scanning, bone marrow biopsy, complete blood counts, lactate dehydrogenase (LDH) levels, and assessment of overall organ function. Staging follows the Lugano modification of the Ann Arbor system, which classifies DLBCL into four stages based on the number and location of involved sites relative to the diaphragm.
The Ann Arbor Staging System at a Glance
| Stage | Description |
|---|---|
| Stage I | Involvement of a single lymph node region or one extranodal site |
| Stage II | Two or more lymph node regions on the same side of the diaphragm |
| Stage III | Lymph node regions on both sides of the diaphragm |
| Stage IV | Widespread involvement of one or more extranodal organs (e.g., liver, bone marrow) |
Risk Stratification with the IPI Score
In addition to anatomical staging, clinicians use the International Prognostic Index (IPI) to further stratify risk. The IPI assigns one point each for age over 60, elevated serum LDH, Eastern Cooperative Oncology Group (ECOG) performance status of 2 or higher, Ann Arbor stage III or IV disease, and more than one extranodal site of involvement. Total IPI scores range from 0 to 5 and help predict overall survival as well as guide treatment intensity.
Molecular profiling has become increasingly important in refining the diagnostic workup. Next-generation sequencing and gene expression profiling can identify the cell-of-origin subtype (GCB vs. ABC) and detect high-risk genetic features such as double-hit status. These results directly influence therapeutic decision-making, particularly in patients who may need intensified regimens beyond standard chemotherapy.
DLBCL Treatment Options, Prognosis, and Survival Rates
The standard first-line treatment for most patients with DLBCL is the R-CHOP regimen, which combines the anti-CD20 monoclonal antibody rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone. This regimen is typically delivered in six cycles over 18 weeks and has transformed outcomes since its introduction in the early 2000s. Clinical trials published in the New England Journal of Medicine demonstrated that adding rituximab to CHOP chemotherapy significantly improved complete response rates and overall survival compared to CHOP alone.
Patients with limited-stage (Stage I–II) disease may receive a shorter course of R-CHOP followed by involved-site radiation therapy, while those with advanced-stage disease generally complete six full cycles of R-CHOP. For patients with double-hit lymphoma or very high-risk IPI scores, more intensive regimens such as DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) may be considered, though evidence supporting their superiority over R-CHOP continues to evolve.
Relapsed or refractory DLBCL — defined as disease that returns after or fails to respond to initial therapy — represents a major clinical challenge. Second-line options include platinum-based salvage chemotherapy regimens followed by high-dose therapy and autologous stem cell transplantation for eligible patients. More recently, CAR-T cell therapy has emerged as a transformative option: axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel have all received FDA approval for relapsed or refractory DLBCL, offering durable remissions in patients who previously had very limited options. Bispecific antibodies such as epcoritamab and glofitamab represent another promising class of agents in this space.
Regarding the DLBCL prognosis and survival rates, approximately 60–70% of patients achieve complete remission with first-line R-CHOP therapy, and a significant proportion remain in long-term remission. The five-year overall survival rate for all stages combined is approximately 55–65%, though outcomes vary widely by stage, IPI score, and molecular subtype. Patients with low-risk IPI scores and limited-stage disease may have five-year survival rates exceeding 80%, while those with high-risk features or double-hit genetics face considerably worse outcomes. Advances in CAR-T therapy and bispecific antibodies are steadily improving the prognosis for relapsed disease.
Frequently Asked Questions
Is DLBCL curable?
Yes, DLBCL is potentially curable, particularly in patients diagnosed at an early stage or with favorable risk features. Approximately 60–70% of patients achieve complete remission with standard R-CHOP chemotherapy, and many remain disease-free long term. Even in relapsed cases, salvage chemotherapy, stem cell transplantation, and CAR-T cell therapy offer curative potential for select patients. Prognosis depends heavily on disease stage, molecular subtype, and overall health at the time of diagnosis.
How does DLBCL differ from other types of non-Hodgkin lymphoma?
DLBCL is distinguished from other non-Hodgkin lymphomas primarily by its aggressive growth rate and B cell origin. Unlike follicular lymphoma, which grows slowly and may be managed with watchful waiting, DLBCL progresses rapidly and requires immediate treatment. Compared to Burkitt lymphoma, another aggressive B cell lymphoma, DLBCL tends to affect older adults and is generally managed with R-CHOP rather than hyper-intensive pediatric-style regimens. Molecular profiling further separates DLBCL into distinct subtypes with different clinical behaviors.
What are the most common side effects of DLBCL treatment?
R-CHOP chemotherapy is associated with several well-documented side effects, including fatigue, nausea, hair loss, increased infection risk due to low white blood cell counts (neutropenia), and peripheral neuropathy from vincristine. Rituximab can cause infusion reactions. Long-term risks include cardiotoxicity from doxorubicin and secondary malignancies. CAR-T cell therapy carries unique risks such as cytokine release syndrome and neurotoxicity. Patients should discuss all potential side effects with their oncology team before starting treatment.
